ClinicalTrials.gg
RecruitingNCT06321887CAESARUpdated Mar 20, 2024

EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD

A Phase 3 interventional study of Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron) and Ferrous fumarate syrup 2.5ml/70mg(45mg elemental iron) in Inflammatory Bowel Disease and Iron Deficiency Anemia, sponsored by Liverpool University Hospitals NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-20.

Sponsored by Liverpool University Hospitals NHS Foundation Trust · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Oct 2023, registered Feb 2024).
  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom — 20 open to participants now, 28 under way, 6 of them phase 3. Inflammatory Bowel Diseases · United Kingdom.

Planned enrollment
57th of 70
30 · median 95
Started
2023
with 4 others
Phase 3
20 of 112
4 open now
Primary completion
2024-10
later than 3 of 27 live
Registered
100th of 112
by date

Among the 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom, this one is the 57th largest by planned enrollment of the 70 interventional ones that give a count, is one of 5 that started in 2023, is one of 20 in phase 3, reaches primary completion later than 3 of the 27 other live ones, and was the 100th registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

20 of the 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom, or all of them as a file.
02

Study summary

Iron deficiency anaemia (IDA) is common in inflammatory bowel disease (IBD). However, although iron is commonly prescribed, the amount of elemental iron needed to achieve clinical efficacy, and the optimal method of supplementation, are under debate. This pilot study aims to investigate the efficacy and safety of low dose and standard dose oral iron preparations for the treatment of IDA in patients with IBD.

Read the detailed description

BACKGROUND:

Anaemia, particularly iron-deficiency anaemia, is a common complication of inflammatory bowel disease (IBD). The prevalence of anaemia (6-74%) and iron deficiency (36-90%) varies widely among reported studies. The predominant cause of iron deficiency in IBD is intestinal blood loss but other factors such as malabsorption and reduced intake may also play a role. Thus, the need for iron supplementation is an often encountered clinical problem in IBD. Although iron is commonly prescribed, the amount of elemental iron needed to achieve clinical efficacy, and the optimal method of supplementation, are under debate. As intravenous (IV) iron supplementation has become safer, calls for increased utilization have appeared. However, there are significant cost implications to using IV iron. On average, a 1-month supply of oral ferrous sulfate costs $12, in comparison with approximately $600-$700 for a treatment cycle of (IV) iron sucrose, excluding the cost of IV administration.

Overall, the comparative studies of IV vs. oral iron do not demonstrate a significant difference in haemoglobin repletion favouring IV iron therapy. Haemoglobin concentrations were similar at the end of treatment in all studies. A single study suggested a superiority for IV iron with a haemoglobin increase greater than 2 g/dl in 47% of the patients on oral iron compared with 66% on IV iron (P = 0.07). However, this could be accounted for by a high withdrawal rate (24%) in the oral iron group. In the largest comparative study, of 196 subjects, median haemoglobin improved similarly, from 8.7 to 12.3 g/dl in the IV group and from 9.1 to 12.1 g/dl in the ferrous sulfate group (P = 0.70). Thus, intravenous iron appears no more effective than oral iron in repletion of iron status as the rate-limiting step appears to be synthesis of red cells, which is not accelerated by IV iron delivery.

The main reason behind the preference of IV iron over oral iron is based on the concern that oral iron may exacerbate IBD. An often-cited study investigating whether oral iron worsens IBD in comparison with IV iron assessed disease activity in 19 IBD patients, 11 with CD and 8 with UC, randomized to either oral ferrous fumarate or IV iron sucrose over a 14-day period. Although the authors argued that disease activity was worsened by oral iron therapy, their use of numerous unconventional assessments weakens this conclusion. The trial was done as a crossover study with a minimum 6-week washout period, so the previous drug therapy may have affected the results. The number of subjects with IBD was small (N = 19). The authors created a synthesized overall disease activity score by combining UC and CD scales and also reported on subscales within activity indexes to identify significant differences. When the two groups were compared, however, there was no statistically significant difference in the overall synthesized disease activity score.

Another factor associated with intolerance of oral iron may be related to the dose of elemental iron administered. In order to maintain iron balance, adult men need to absorb 1-1.5 mg/d, menstruating women need 1-3 mg/d, and pregnant women need approximately 4-5 mg/d. Based on this, the recommended daily allowance of elemental iron is about 8 mg in adult men and postmenopausal women, 18 mg in premenopausal women, and 27 mg in pregnant women. However, most studies investigating the efficacy of oral iron have used a typical dose of 150-200mg/d of elemental iron, 10-20 fold in excess of the recommended daily allowance. Because of the 20% incidence level of intolerance at these conventional doses of elemental iron, recent studies have investigated the efficacy and side effects associated with low-dose oral iron supplementation. A study in the elderly (age >80) randomised 90 patients with iron-deficiency anaemia to 15, 50, or 150 mg of daily oral elemental iron over 2 months. All three dosage groups experienced a similar, statistically significant increase in haemoglobin after 2 months. These studies have not been done in IBD.

This pilot study aims to investigate the efficacy and safety of low dose and standard dose oral iron preparations.

HYPOTHESIS:

Low dose oral iron is effective and safe in the treatment of iron deficiency anaemia in inflammatory bowel disease.

03

Conditions studied

  • Inflammatory Bowel Disease
  • Iron Deficiency Anemia
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is willing to participate in the study and has signed the .
  • Patients aged 18-80 years.
  • Patients diagnosed with Crohn's disease or ulcerative colitis diagnosed by conventional clinical, radiological and histological criteria.
  • Remission or active disease.
  • level 7-13 g/dL men, 7-12 g/dL women and ferritin \<30, normal B12 and folate (or ferritin \<100 but iron sats \<16 in the presence of inflammation defined as CRP>5mg/L, faecal calprotectin>250 microgram/g and presence of endoscopic inflammation).

Exclusion criteria

Exclusion Criteria:

  • Patients under 18 or unable to give .
  • Patients with advanced liver disease.
  • Patients with advanced renal disease with \<45ml/min
  • Previous intolerance to even low doses of oral iron
  • Patients with severe cardiovascular disease defined as previous unstable angina and or previous MI without intervention.
  • Participation in other trials in the last 3 months.
  • Serious inter-current infection or other active disease (including renal and hepatic disease) and recently diagnosed gastrointestinal tract cancers
  • Pregnant, post-partum (\<3months) or breast feeding females
  • Erythropoietin therapy.
  • Recent blood transfusion within 30 days.
  • Recent iron infusion within 30 days.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    STAGE 1

    The first stage shall recruit 10 patients and is used to assess the incidence of oral iron related toxicity. Patients will be prescribed: • Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron) daily for 8 weeks. If patients experience toxicity (defined as symptoms not tolerated by the patient), the trial medication would be stopped and IV Iron treatment given. If toxicity occurs in 2 or more patients where we have to stop treatment, we will continue to recruit 30 patients only to the Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron) daily for 8 weeks. If the toxicity is acceptable and the Hb improves, we will continue to recruit to 22.5mg oral iron/day. If the toxicity is acceptable but there is no improvement in haemoglobin the next patients will be recruited to stage 2.

    Drug: Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron)

  • Experimental
    STAGE 2

    Ten subjects each will then be sequentially assigned to one of the following groups: * Ferrous fumarate syrup 5ml/140mg (45mg elemental iron) daily for 8 weeks. * Ferrous fumarate syrup 5ml/140mg twice daily (90mg elemental iron) for 8 weeks. If 2 or more patients experience toxicity at Ferrous fumarate syrup 5ml/140mg (45mg elemental iron) or Ferrous fumarate syrup 5ml/140mg twice daily (90mg elemental iron) we will reduce the dose to the previous level of Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron) and continue to recruit. 30 patients shall be used to estimate the change in haemoglobin between baseline and the final analysis point. If no dose reduction is required, only the last 20 patients shall be used to assess haemoglobin. The overall endpoint is the haemoglobin level.

    Drug: Ferrous fumarate syrup 2.5ml/70mg(45mg elemental iron) · Drug: Ferrous fumarate syrup 2.5ml/70mg (90mg elemental iron)

Interventions

  • DrugFerrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron)

    Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron) daily for 8 weeks (N=10).

  • DrugFerrous fumarate syrup 2.5ml/70mg(45mg elemental iron)

    Ferrous fumarate syrup 5ml/140mg (45mg elemental iron) daily for 8 weeks (N=10).

  • DrugFerrous fumarate syrup 2.5ml/70mg (90mg elemental iron)

    Ferrous fumarate syrup 5ml/140mg twice daily (90mg elemental iron) for 8 weeks (N=10).

06

What researchers measure

Primary outcomes

  1. Change in haemoglobin concentration from baseline to week 8.

    Measured using serum haemoglobin concentration measured in g/L, taken at week 0 and week 8.

    Time frame: 8 weeks

Secondary outcomes

  1. Assessment of iron stores at baseline and week 8

    Measured using serum ferritin values measured in ug/L taken at week 0 and week 8.

    Time frame: 8 weeks

  2. Assessment of faecal calprotectin at baseline and week 8

    Measures on a continuous numeric scale ranging from 21ug/g to 2099ugug. Values outside these thresholds reported as \<20ug/g to \>2100ug/g.

    Time frame: 8 weeks

  3. Assessment of IBD severity. For ulcerative colitis this will be done using simple colitis clinical activity index (SCCAI). Values calculated at week 0 and week 8.

    SCCAI measured from 0-19 on a continuous numeric scale.

    Time frame: 8 weeks

  4. Assessment of IBD severity. For Crohn's disease (or IBD-unclassified) the Harvey Bradshaw Index (HBI) will be used. Values calculated at week 0 and week 8.

    HBI measured from 0-28 on a continuous numeric scale.

    Time frame: 8 weeks

  5. Assessment of quality of life using the IBD-QUK score at baseline and week 8

    IBD-QUK measured from 0-96 on a continuous numeric scale, then expressed as a percentage from 0-100%.

    Time frame: 8 weeks

  6. Assessment of patient global assessment of symptom severity by visual analogue score at baseline and week 8.

    A series of eight questions, each comprising a score. The higher the sum of scores, the more severe the symptom profile. Question one pertains to bowel frequency (total number of stools per week), questions two through eight refer to specific gastrointestinal complaints, the severity of which are scored by placing a marker on a 10cm visual scale - the total length of the line marked denotes the severity score for each question.

    Time frame: 8 weeks

  7. Assessment of fatigue at baseline and week 8 using IBD-F fatigue score

    Scored using a series of 35 questions, each scored from 0 to 4. The higher the total score (out of a possible total of 140), the higher the severity of fatigue.

    Time frame: 8 weeks

  8. Assessment of possible drug-related side effects: nausea, diarrhoea, mood disturbance, sleep disturbance - will all be assessed at baseline and week 8.

    Measured using a binary outcome (yes/no) measure when asked whether any of the aforementioned symptoms have been experienced by the participant during the study period.

    Time frame: 8 weeks

Other outcomes

  1. Experimental arm 1: Assessment of faecal metabolome composition at baseline and week 8

    Faecal metabolome will be assessed by analysing the faecal headspace volatile organic compounds using semi-quantitative solid-phase microextraction gas chromatography mass spectrometry. Data will be presented using the relative abundance metrics for the key metabolites identified.

    Time frame: 8 weeks

  2. Experimental arm 2: Assessment of faecal microbiota composition at baseline and week 8

    Faecal microbiome will be assessed using high throughput metagenomic sequencing. Data will be presented using relative abundance metrics for the key microbes identified.

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
  • Liverpool University Foundation NHS Trust
    Liverpool, United Kingdom
    Recruiting
08

References and documents

Publications

  • Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn's disease. Aliment Pharmacol Ther. 2006 Dec;24(11-12):1507-23. doi: 10.1111/j.1365-2036.2006.03146.x. PubMed 17206940 ↗
  • Gasche C, Berstad A, Befrits R, Beglinger C, Dignass A, Erichsen K, Gomollon F, Hjortswang H, Koutroubakis I, Kulnigg S, Oldenburg B, Rampton D, Schroeder O, Stein J, Travis S, Van Assche G. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007 Dec;13(12):1545-53. doi: 10.1002/ibd.20285. PubMed 17985376 ↗
  • Hodges P, Gee M, Grace M, Thomson AB. Vitamin and iron intake in patients with Crohn's disease. J Am Diet Assoc. 1984 Jan;84(1):52-8. PubMed 6690565 ↗
  • Gisbert JP, Gomollon F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol. 2008 May;103(5):1299-307. doi: 10.1111/j.1572-0241.2008.01846.x. PubMed 18477354 ↗
  • Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol. 2010 Nov;7(11):599-610. doi: 10.1038/nrgastro.2010.151. Epub 2010 Oct 5. PubMed 20924367 ↗
  • Schroder O, Mickisch O, Seidler U, de Weerth A, Dignass AU, Herfarth H, Reinshagen M, Schreiber S, Junge U, Schrott M, Stein J. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study. Am J Gastroenterol. 2005 Nov;100(11):2503-9. doi: 10.1111/j.1572-0241.2005.00250.x. PubMed 16279906 ↗
  • Erichsen K, Ulvik RJ, Nysaeter G, Johansen J, Ostborg J, Berstad A, Berge RK, Hausken T. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol. 2005 Sep;40(9):1058-65. doi: 10.1080/00365520510023198. PubMed 16165718 ↗
  • Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, Sambuelli AM, D'Haens G, Gasche C. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008 May;103(5):1182-92. doi: 10.1111/j.1572-0241.2007.01744.x. Epub 2008 Mar 26. PubMed 18371137 ↗
  • Lindgren S, Wikman O, Befrits R, Blom H, Eriksson A, Granno C, Ung KA, Hjortswang H, Lindgren A, Unge P. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol. 2009;44(7):838-45. doi: 10.1080/00365520902839667. PubMed 19330567 ↗
  • Munoz M, Villar I, Garcia-Erce JA. An update on iron physiology. World J Gastroenterol. 2009 Oct 7;15(37):4617-26. doi: 10.3748/wjg.15.4617. PubMed 19787824 ↗
  • Hallberg L, Ryttinger L, Solvell L. Side-effects of oral iron therapy. A double-blind study of different iron compounds in tablet form. Acta Med Scand Suppl. 1966;459:3-10. doi: 10.1111/j.0954-6820.1966.tb19403.x. No abstract available. PubMed 5957969 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Oct 2024, 11 months after the start.

Of 28 phase 3 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 83. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2024
First posted
Mar 20, 2024
StartActual
Oct 20, 2023
Primary completionEst.
Oct 1, 2024
CompletionEst.
Oct 1, 2025
Last update
Mar 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06321887
Lead sponsor
Liverpool University Hospitals NHS Foundation Trust
Responsible party
Sponsor
First posted
Mar 20, 2024
Start date
Oct 20, 2023
Primary completion
Oct 1, 2024 (estimated)
Completion
Oct 1, 2025 (estimated)
Last update
Mar 20, 2024

Study contacts

S Subramanian
Contact
RGT@liverpoolft.nhs.uk
01517062000
T Conley
Contact
RGT@liverpoolft.nhs.uk
01517062000
T Conley
principal investigator · Liverpool University Foundation NHS Trust

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion